Werewolf Therapeutics, Inc.
HOWL
$0.39
$0.001.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -48.91% | -36.48% | -21.40% | 12.33% | 16.14% |
| Gross Profit | 89.88% | 35.09% | 18.50% | -21.48% | -47.07% |
| SG&A Expenses | -6.26% | -20.01% | -15.37% | -14.30% | -7.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.21% | -31.65% | -19.61% | 2.89% | 7.97% |
| Operating Income | 64.97% | 30.60% | 17.55% | -8.15% | -25.15% |
| Income Before Tax | 52.68% | 22.30% | 13.75% | -17.26% | -36.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.68% | 22.30% | 13.75% | -17.26% | -36.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.68% | 22.30% | 13.75% | -17.26% | -36.13% |
| EBIT | 64.97% | 30.60% | 17.55% | -8.15% | -25.15% |
| EBITDA | 69.25% | 31.11% | 17.74% | -8.63% | -26.13% |
| EPS Basic | 55.37% | 26.29% | 17.96% | -8.31% | -22.09% |
| Normalized Basic EPS | 66.69% | 31.16% | 17.30% | -9.25% | -23.27% |
| EPS Diluted | 53.69% | 25.92% | 17.82% | -6.41% | -19.51% |
| Normalized Diluted EPS | 66.86% | 31.14% | 17.24% | -9.59% | -23.70% |
| Average Basic Shares Outstanding | 7.55% | 6.39% | 6.19% | 8.88% | 13.12% |
| Average Diluted Shares Outstanding | 7.99% | 6.52% | 6.33% | 8.54% | 12.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |